Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
As the most prevalent pathogen among transplant patients, cytomegalovirus (CMV) affects up to three-quarters of all solid organ transplant recipients. While we have made great strides in preventing CMV infection and disease in the early post-transplant period, late CMV infection and indirect effects due to viral immunomodulation remain problematic. Changing immunosuppression practices, including the increasing use of T-cell depleting induction antibodies, have the potential to affect the risk for CMV infection and disease, even in the face of good prophylactic and preemptive therapy. The purpose of this review article is to discuss the impact of CMV infection on long-term allograft outcomes and to re-evaluate the risks and management strategies for prevention of CMV in the framework of evolving modern immunosuppressive strategies.
Fisher
R A
RA
VCU Department of Surgery, Division of Transplantation Surgery, Virginia Commonwealth University, Richmond, Virginia 23298, USA. rafisher@vcu.edu
D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000517:prevention & control / Q000821:virology; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016377:Organ Transplantation / Q000009:adverse effects; D018570:Risk Assessment; D016896:Treatment Outcome
D000998:Antiviral Agents; D007166:Immunosuppressive Agents